JP2018512402A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512402A5
JP2018512402A5 JP2017548142A JP2017548142A JP2018512402A5 JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5 JP 2017548142 A JP2017548142 A JP 2017548142A JP 2017548142 A JP2017548142 A JP 2017548142A JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5
Authority
JP
Japan
Prior art keywords
immunoconjugate
immune complex
subject
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017548142A
Other languages
English (en)
Japanese (ja)
Other versions
JP6847846B2 (ja
JP2018512402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/022085 external-priority patent/WO2016145354A1/en
Publication of JP2018512402A publication Critical patent/JP2018512402A/ja
Publication of JP2018512402A5 publication Critical patent/JP2018512402A5/ja
Application granted granted Critical
Publication of JP6847846B2 publication Critical patent/JP6847846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017548142A 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略 Expired - Fee Related JP6847846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562132251P 2015-03-12 2015-03-12
US62/132,251 2015-03-12
US201562267386P 2015-12-15 2015-12-15
US62/267,386 2015-12-15
PCT/US2016/022085 WO2016145354A1 (en) 2015-03-12 2016-03-11 Dosing strategies for targeting epcam positive bladder cancer

Publications (3)

Publication Number Publication Date
JP2018512402A JP2018512402A (ja) 2018-05-17
JP2018512402A5 true JP2018512402A5 (enExample) 2019-04-18
JP6847846B2 JP6847846B2 (ja) 2021-03-24

Family

ID=56879327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548142A Expired - Fee Related JP6847846B2 (ja) 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略

Country Status (8)

Country Link
US (1) US10583198B2 (enExample)
EP (1) EP3268041A4 (enExample)
JP (1) JP6847846B2 (enExample)
CN (1) CN107580501A (enExample)
AU (1) AU2016228760B2 (enExample)
CA (1) CA2979400A1 (enExample)
HK (1) HK1249731A1 (enExample)
WO (1) WO2016145354A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639301T3 (es) 2003-04-30 2017-10-26 Universität Zürich Procedimientos de tratamiento de cáncer usando una inmunotoxina
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
HK1249731A1 (zh) 2015-03-12 2018-11-09 Viventia Bio Inc. 针对就上皮细胞黏着分子呈阳性反应的膀胱癌的剂量技巧
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー, インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
EP4599893A3 (en) * 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
WO2023222024A1 (en) * 2022-05-18 2023-11-23 Bj Bioscience Inc. Bispecific antibodies targeting epcam and cd3
CN115109164A (zh) * 2022-06-07 2022-09-27 博际生物医药科技(杭州)有限公司 靶向epcam和cd3的双特异性抗体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
JP4336452B2 (ja) 1997-12-08 2009-09-30 メルク パテント ゲーエムベーハー 標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
EP1171468B1 (en) 1999-04-09 2008-07-02 Universität Zürich Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
PL374495A1 (en) 2001-10-15 2005-10-31 Immunomedics, Inc. Direct targeting binding proteins
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
ES2639301T3 (es) 2003-04-30 2017-10-26 Universität Zürich Procedimientos de tratamiento de cáncer usando una inmunotoxina
MXPA06010716A (es) 2004-03-19 2007-02-21 Merck Patent Gmbh Proteinas bouganin modificadas, citotoxinas y metodos y usos de las mismas.
AU2005252275B2 (en) 2004-06-10 2011-07-21 Viventia Bio Inc. Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
US8318472B2 (en) 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CN102387815A (zh) 2009-04-08 2012-03-21 海因茨·福尔斯蒂奇 用于治疗癌症的具鹅膏蕈毒素的靶结合部分
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
KR20160006697A (ko) 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
HK1249731A1 (zh) 2015-03-12 2018-11-09 Viventia Bio Inc. 针对就上皮细胞黏着分子呈阳性反应的膀胱癌的剂量技巧
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2018512402A5 (enExample)
JP2016528247A5 (enExample)
JP2014158469A5 (enExample)
JP2018518454A5 (enExample)
JP2016520082A5 (enExample)
JP2017506217A5 (enExample)
JP2016094424A5 (enExample)
JP2019519499A5 (enExample)
RU2019106663A (ru) Комбинированная терапия рака
JP2012501626A5 (enExample)
JP2013520442A5 (enExample)
JP2009533367A5 (enExample)
JP2018505177A5 (enExample)
JP2011506483A5 (enExample)
JP2018508512A5 (enExample)
JP2015534579A5 (enExample)
JP2017501167A5 (enExample)
JP2016519650A5 (enExample)
SI2719708T1 (en) Material and methods for treating or preventing HER-3-related diseases
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2008528486A5 (enExample)
JP2015517529A5 (enExample)
JP2020510039A5 (enExample)
JP2018529661A5 (enExample)